The A-Team was busy this week representing Aetion at conferences near and far—from Boston to Tokyo.
On Monday, our CEO, Carolyn Magill, was at the Longwood Annual Winter Meeting to speak on the panel “Getting to drug approval” with Emil Kakkis of Ultragenyx Pharmaceutical Inc., Sandy Macrae of Sangamo Therapeutics, Inc., Roger Tung of Concert Pharmaceuticals, Inc., and Paula Soteropoulos of Akcea Therapeutics.
On Tuesday, Carolyn joined the panel "Building a strong case for real-world evidence" at the Digital Healthcare Innovation Summit to discuss pharma-tech partnerships working to advance RWE with Rachel Sha of Sanofi, Tom Neyarapally of Sema4, and Shrujal Baxi of Flatiron Health.
Also on Tuesday, Jeremy Rassen, our Co-founder, President, and Chief Science Officer, gave a keynote talk at HIMSS & Health 2.0 Japan 2019, titled "Using real-world evidence to answer critical questions in health care."
Way to go, team!
Please join us on Tuesday, December 3, at 9:30AM EST for a webinar with eyeforpharma on how to use real-world evidence to assess drug value. Edward Lee of UCB, Pamela Bradt, MD, MPH of the Institute for Clinical and Economic Review, and Enkeleida Nikai-Fitzgerald of Janssen Europe, Middle East & Africa (EMEA) will join our CEO Carolyn Magill to discuss best practices for determining drug pricing and value using RWE, what this means for your evidence generation strategy, and how to address the risk-sharing equation to bring the right treatments to the right patients.
Register here: http://glassdoor.com/slink.htm?key=vMLDA
The Aetion team had a great week in Copenhagen for ISPOR Europe 2019. Jeremy Rassen joined the panel on the third plenary session, “Big health care data: Opportunities for research and learning,” closing out the conference with a discussion on the false dichotomies between RCTs and RWE. We’re proud of the great work our team showcased, including presentations by Sebastian Schneeweiss, Jeremy Rassen, Yin Ho, Andrew Weckstein, and Ashley Jaksa.
This week, we welcome a group of esteemed guests for our first annual Aetion Summit: Evidence at the Apex. We look forward to two days of great conversation and learning about real-world evidence with leaders in biopharma, academia, and medicine, including a keynote from our newest board member, Scott Gottlieb. Follow #aetionsummit for updates and live coverage.
This afternoon, Aetion's eclectic collective is well-represented at two industry events. Our General Counsel Lori Bennett will speak at Corporate Counsel's Women, Innovation, and Power in Law event in Washington, DC. In parallel, Kristen Coletto, Senior Director of Product, will speak at The Wharton School's 2019 Wharton Health Care Conference on Artificial Intelligence on the panel "From data to drugs: Using AI to unlock therapeutic advances" — be sure to join if you're there!
On October 3, Sebastian Schneeweiss presented on using real-world data and real-world evidence to support regulatory decision-making at the Duke-Margolis Center for Health Policy event, #RWE2019. See his talk here: http://glassdoor.com/slink.htm?key=vMY1s
We’re pleased to announce that Dr. Scott Gottlieb has joined our Board of Directors. During his tenure as FDA Commissioner, Dr. Gottlieb was a champion for the FDA’s use of real-world evidence, and his experience as a physician, regulator, and advocate will help us to continue to advance #RWE in partnership with our clients and partners.
Learn more about this exciting news: http://glassdoor.com/slink.htm?key=vMy5B